Wells Fargo & Company MN Buys 2,972 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Wells Fargo & Company MN raised its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 21.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,928 shares of the company's stock after acquiring an additional 2,972 shares during the quarter. Wells Fargo & Company MN owned about 0.06% of Krystal Biotech worth $2,652,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in KRYS. US Bancorp DE increased its holdings in Krystal Biotech by 8.7% during the 4th quarter. US Bancorp DE now owns 1,027 shares of the company's stock worth $161,000 after acquiring an additional 82 shares during the period. Crossmark Global Holdings Inc. increased its holdings in shares of Krystal Biotech by 5.5% in the fourth quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company's stock worth $362,000 after purchasing an additional 121 shares during the period. Perigon Wealth Management LLC raised its position in shares of Krystal Biotech by 1.5% in the fourth quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company's stock worth $1,200,000 after buying an additional 123 shares in the last quarter. Xponance Inc. boosted its stake in Krystal Biotech by 9.5% during the fourth quarter. Xponance Inc. now owns 1,785 shares of the company's stock valued at $280,000 after buying an additional 155 shares during the period. Finally, Commonwealth Equity Services LLC increased its stake in Krystal Biotech by 4.1% in the 4th quarter. Commonwealth Equity Services LLC now owns 4,866 shares of the company's stock worth $762,000 after acquiring an additional 190 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company's stock.

Analyst Ratings Changes

KRYS has been the subject of a number of research analyst reports. Citigroup lifted their price target on Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research report on Thursday, February 20th. Cantor Fitzgerald reissued an "overweight" rating and issued a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th. Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 target price for the company. HC Wainwright raised their price target on Krystal Biotech from $221.00 to $240.00 and gave the company a "buy" rating in a research report on Monday. Finally, Chardan Capital upped their price objective on Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a report on Thursday, February 20th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $222.71.

Krystal Biotech Stock Performance

NASDAQ:KRYS traded up $1.67 during midday trading on Monday, reaching $169.73. 167,657 shares of the stock traded hands, compared to its average volume of 295,598. The stock has a market capitalization of $4.90 billion, a P/E ratio of 56.77 and a beta of 0.75. The company has a fifty day moving average of $176.37 and a 200 day moving average of $171.56. Krystal Biotech, Inc. has a 12 month low of $141.72 and a 12 month high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. The company had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. Krystal Biotech's revenue for the quarter was up 116.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.30 earnings per share. On average, analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Insider Activity

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the sale, the chief accounting officer now directly owns 12,604 shares in the company, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the transaction, the insider now owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their position. The disclosure for this sale can be found here. Insiders own 13.70% of the company's stock.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).